Literature DB >> 7773216

Effect of antimicrobial prophylaxis on hematopoietic recovery following autologous bone marrow transplantation: ciprofloxacin versus co-trimoxazole.

K R Imrie1, H M Prince, F Couture, J M Brandwein, A Keating.   

Abstract

We evaluated the effect of oral ciprofloxacin on neutrophil recovery in 20 consecutive patients undergoing autologous bone marrow transplantation (BMT) for malignant lymphoma and compared the results with a control group of 20 patients receiving co-trimoxazole and folinic acid. Both groups started the prophylactic antibiotic as well as granulocyte-macrophage colony-stimulating factor (GM-CSF) the day after marrow infusion and continued the former until the onset of febrile neutropenia (median duration of treatment 6 days for co-trimoxazole and 7 days for ciprofloxacin). The time of attain an absolute neutrophil count > or = 0.5 x 10(9)/L was significantly shorter in patients receiving ciprofloxacin (16 days vs 22 days; P = 0.006). There was no difference in time to attain a platelet count > or = 20 x 10(9)/L independent of transfusion or in time to the first febrile episode or incidence of bacteremia. We conclude that antibiotic prophylaxis with ciprofloxacin results in more rapid neutrophil recovery than prophylaxis with co-trimoxazole. This may result from a myelosuppressive effect of co-trimoxazole or an enhancement of neutrophil recovery by ciprofloxacin, or both.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7773216

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  11 in total

Review 1.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Pneumocystis jiroveci Pneumonia in an Atypical Host.

Authors:  Raquel E Reinbolt; Shadia Alam; Rachel Layman; Charles Shapiro; Maryam Lustberg
Journal:  Clin Breast Cancer       Date:  2011-12-01       Impact factor: 3.225

3.  Incidence, clinical presentation, and outcomes of Pneumocystis pneumonia when utilizing Polymerase Chain Reaction-based diagnosis in patients with Hodgkin lymphoma.

Authors:  Jason N Barreto; Carrie A Thompson; Patrick M Wieruszewski; Amanda G Pawlenty; Kristin C Mara; Ashley L Potter; Pritish K Tosh; Andrew H Limper
Journal:  Leuk Lymphoma       Date:  2020-07-05

Review 4.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.

Authors:  Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Liat Vidal; Theresa A Lawrie; Marianne D van de Wetering; Leontien C M Kremer; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

Review 5.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 6.  [Febrile neutropenia: practical aspects].

Authors:  P Harten; B Seyfarth; N Schmitz
Journal:  Med Klin (Munich)       Date:  1998-10-15

7.  Revisiting Co-trimoxazole Prophylaxis for African Adults in the Era of Antiretroviral Therapy: A Randomized Controlled Clinical Trial.

Authors:  Matthew B Laurens; Randy G Mungwira; Nginache Nampota; Osward M Nyirenda; Titus H Divala; Maxwell Kanjala; Felix A Mkandawire; Lufina Tsirizani Galileya; Wongani Nyangulu; Edson Mwinjiwa; Matthew Downs; Amy Tillman; Terrie E Taylor; Jane Mallewa; Christopher V Plowe; Joep J van Oosterhout; Miriam K Laufer
Journal:  Clin Infect Dis       Date:  2021-09-15       Impact factor: 9.079

8.  An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital.

Authors:  L J Worth; M J Dooley; J F Seymour; L Mileshkin; M A Slavin; K A Thursky
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

9.  A Novel Encochleated Formulation Improves Atovaquone Activity in a Murine Model of Pneumocystis Pneumonia.

Authors:  Melanie T Cushion; Parag Kumar; Ruying Lu; Alan Ashbaugh; Lilian W Adeojo; Raul Alfaro; Raphael Mannino; Edmund Tramont; Joseph A Kovacs
Journal:  J Infect Dis       Date:  2021-07-15       Impact factor: 5.226

Review 10.  Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure.

Authors:  Vijay K Singh; Thomas M Seed
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.